Table 4 Examples of other Swiss cost-effectiveness analyses (CEA)
Study (Ref) | Indication | Comparison | Cost- effectiveness |
|---|---|---|---|
[45] | CEA of quadrivalent HPV vaccine in girls aged 11 years over lifetime | Cytological screening vs. cytological screening with vaccination | €17'337/QALY* |
[46] | CEA of eplerenone in patients with left ventricular dysfunction after myocardial infarction (EPHESUS study) | Eplerenone vs. placebo | €7'558/QALY*1 to €15'977/QALY*1 |
[47] | Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer | Trastuzumab vs. standard care | €40'505/LYG2 €19'673/LYG3 |